Alamar Biosciences Launches NULISAqpcr BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer’s Disease Research
New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next…
Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort
NULISAseqâ„¢ CNS Disease Panel 120 and Inflammation Panel 250 to Power Biomarker…
Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer’s Association International Conference (AAIC)
Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters…
Alamar Biosciences, Alzheimer’s Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer’s Disease.
Multi-center project will profile over 40,000 samples using ultra-sensitive NULISAâ„¢ technology. FREMONT,…